Prostate Cancer
Bayer Presents Clinical Data on Alpharadin in Metastatic Castration-Resistant Prostate Cancer CRPC
Published in Pharma Law Weekly, June 15th, 2010
Bayer HealthCare will present a combined analysis from Phase I and II clinical trials evaluating the safety and efficacy of one of its lead investigational cancer treatments, Alpharadin™ (radium-223 chloride), in castration-resistant prostate cancer (CRPC) that has spread to the bones (metastases). These data, along with data from a Phase I pharmacokinetic and biodistribution study of Alpharadin, will be presented at the 46th Annual Meeting of the American Society of Clinical Oncology (ASCO), June 4-8, 2010, in Chicago, IL.
"The analysis of the Phase I and II data presented at ASCO helped to provide the basis for the ongoing global Phase III clinical trial of...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Pharma Law Weekly
Source: Pharma Law Weekly (2010-06-15)
More Articles from Pharma Law Weekly
- AB SCIEX
Anti-Doping Enforcement Efforts at the 2010 FIFA World Cup(TM) Enhanced by State-of-the-art Testing Solution from AB SCIEX - Biopharmaceuticals
Array BioPharma to Present at the Jefferies 2010 Global Life Sciences Conference - Multiple Sclerosis
Bayer HealthCare Launches First iPhone Application with Personalized Tools to Assist People on Betaseron(R) interferon beta-1b in Managing Their Multiple Sclerosis Treatment - Biotechnology Business
BioSpecifics Technologies Corp. Announces Board Authorization of up to $2 Million Share Repurchase Program - More from this issue of Pharma Law Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
